Verastem was named a finalist for the 2026 Prix Galien USA award in rare/orphan diseases for its approved therapy in KRAS-mutated recurrent low-grade serous ova

Verastem was named a finalist for the 2026 Prix Galien USA award in rare/orphan diseases for its approved therapy in KRAS-mutated recurrent low-grade serous ovarian cancer. The recognition comes as the biotech advances a Phase 2 KRAS G12D lung cancer program.